Plain-English translation of NCT07225361 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is studying (Briumvi), a medication that works by targeting certain immune cells involved in multiple sclerosis. Researchers want to learn how well this treatment works for people with early relapsing MS and how patients tolerate it over time. The study will follow you for about two years to see how the medication affects your disease.
Multiple sclerosis can be unpredictable and debilitating, especially in its early stages. This trial exists to understand whether this medication can help control symptoms and slow disease progression in people newly diagnosed with relapsing MS.
You likely qualify if…
You likely don't qualify if…
You will receive the medication on a regular schedule (every 24 weeks or as your insurance covers) as part of your normal medical care. You'll have study visits at the start, and then every 24 weeks for about two years, where you'll complete surveys about how the medication is working, any side effects, and your MS symptoms. Between visits, a study coordinator will check in with you every 24 weeks by phone to make sure everything is going smoothly and to ask about any changes in your medications or symptoms.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States